A Real-World Pharmacovigilance Study of Ceftazidime/Avibactam : Data Mining of the Food and Drug Administration Adverse Event Reporting System Database
© 2024, The American College of Clinical Pharmacology..
Ceftazidime/avibactam (CAZ/AVI) is a combination of a well-known third-generation, broad-spectrum cephalosporin with a new beta-lactamase inhibitor that has been approved for the treatment of various infectious diseases (especially multidrug-resistant Gram-negative bacterial infections) by the Food and Drug Administration (FDA). The current study extensively assessed CAZ/AVI-related adverse events (AEs) in the real world through data mining of the FDA Adverse Event Reporting System (FAERS) database to better understand toxicities. The signals of CAZ/AVI-related AEs were quantified using disproportionality analyses, including the reporting odds ratio, the proportional reporting ratio, the Bayesian confidence propagation neural network, and the multi-item gamma Poisson shrinker algorithms. Out of 10,114,815 records retrieved from the FAERS database, 628 cases were identified, where CAZ/AVI was implicated as the primary suspect drug. A total of 61 preferred terms with significant disproportionality that simultaneously met the criteria of all four algorithms were retained. Several unexpected safety signals may also occur, including melena, hypernatremia, depressed level of consciousness, brain edema, petechiae, delirium, and shock hemorrhagic. The median onset time for AEs associated with CAZ/AVI was 4 days, with most cases occurring within 3 days after CAZ/AVI initiation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of clinical pharmacology - (2024) vom: 20. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yao, Haiping [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ceftazidime/avibactam |
|---|
| Anmerkungen: |
Date Revised 20.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/jcph.2420 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368657418 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368657418 | ||
| 003 | DE-627 | ||
| 005 | 20240220232424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcph.2420 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM368657418 | ||
| 035 | |a (NLM)38375685 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yao, Haiping |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Real-World Pharmacovigilance Study of Ceftazidime/Avibactam |b Data Mining of the Food and Drug Administration Adverse Event Reporting System Database |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024, The American College of Clinical Pharmacology. | ||
| 520 | |a Ceftazidime/avibactam (CAZ/AVI) is a combination of a well-known third-generation, broad-spectrum cephalosporin with a new beta-lactamase inhibitor that has been approved for the treatment of various infectious diseases (especially multidrug-resistant Gram-negative bacterial infections) by the Food and Drug Administration (FDA). The current study extensively assessed CAZ/AVI-related adverse events (AEs) in the real world through data mining of the FDA Adverse Event Reporting System (FAERS) database to better understand toxicities. The signals of CAZ/AVI-related AEs were quantified using disproportionality analyses, including the reporting odds ratio, the proportional reporting ratio, the Bayesian confidence propagation neural network, and the multi-item gamma Poisson shrinker algorithms. Out of 10,114,815 records retrieved from the FAERS database, 628 cases were identified, where CAZ/AVI was implicated as the primary suspect drug. A total of 61 preferred terms with significant disproportionality that simultaneously met the criteria of all four algorithms were retained. Several unexpected safety signals may also occur, including melena, hypernatremia, depressed level of consciousness, brain edema, petechiae, delirium, and shock hemorrhagic. The median onset time for AEs associated with CAZ/AVI was 4 days, with most cases occurring within 3 days after CAZ/AVI initiation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FAERS | |
| 650 | 4 | |a MDR-GNB | |
| 650 | 4 | |a ceftazidime/avibactam | |
| 650 | 4 | |a data mining | |
| 650 | 4 | |a pharmacovigilance | |
| 700 | 1 | |a Wang, Yanyan |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Zhixiong |e verfasserin |4 aut | |
| 700 | 1 | |a Gan, Guoping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacology |d 1973 |g (2024) vom: 20. Feb. |w (DE-627)NLM000005576 |x 1552-4604 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:20 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcph.2420 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 20 |c 02 | ||